Maarten Boers

List of Publications by Year
in descending order

322 papers	28,627 citations	15504 65 h-index	5539 163 g-index
344 all docs	344 docs citations	344 times ranked	19418 citing authors

#	Article	IF	Citations
1	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
2	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 727-735.	6.7	2,531
3	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
4	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.9	1,688
5	The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism, 1993, 36, 729-740.	6.7	1,388
6	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet, The, 1997, 350, 309-318.	13.7	949
7	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
8	How to select outcome measurement instruments for outcomes included in a â€œCore Outcome Setâ€•â€" a practical guideline. Trials, 2016, 17, 449.	1.6	659
9	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.9	657
10	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	5.0	625
11	Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. Journal of Rheumatology, 1997, 24, 799-802.	2.0	524
12	COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention. Arthritis and Rheumatism, 2002, 46, 347-356.	6.7	517
13	OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials, 2007, 8, 38.	1.6	420
14	The OMERACT filter for Outcome Measures in Rheumatology. Journal of Rheumatology, 1998, 25, 198-9.	2.0	415
15	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Annals of the Rheumatic Diseases, 2006, 65, 285-293.	0.9	402
16	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Annals of the Rheumatic Diseases, 2002, 61, 718-722.	0.9	395
17	Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis and Rheumatism, 2004, 50, 36-42.	6.7	345
18	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2007, 66, 1560-1567.	0.9	325

#	Article	IF	Citations
19	Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRÉ Investigation. Annals of the Rheumatic Diseases, 2009, 68, 1395-1400.	0.9	319
20	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis and Rheumatism, 2009, 61, 1571-1579.	6.7	318
21	Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. Journal of Pain, 2019, 20, 245-263.	1.4	283
22	Core outcome measurement instruments for clinical trials in nonspecific low back pain. Pain, 2018, 159, 481-495.	4.2	263
23	Core outcome domains for clinical trials in non-specific low back pain. European Spine Journal, 2015, 24, 1127-1142.	2.2	259
24	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Annals of the Rheumatic Diseases, 2016, 75, 952-957.	0.9	258
25	Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2003, 62, 842-845.	0.9	240
26	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2013, 72, 1905-1913.	0.9	220
27	COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Medical Research Methodology, 2020, 20, 293.	3.1	205
28	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. The Cochrane Library, 2007, , CD006356.	2.8	201
29	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis and Rheumatism, 2008, 59, 1371-1377.	6.7	186
30	Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis and Rheumatism, 2003, 48, 1771-1774.	6.7	174
31	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Annals of the Rheumatic Diseases, 2008, 67, 1360-1364.	0.9	172
32	Towards global consensus on outcome measures for atopic eczema research: results of the <scp>HOME II</scp> meeting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1111-1117.	5.7	169
33	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the Rheumatic Diseases, 2013, 72, 204-210.	0.9	160
34	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Annals of the Rheumatic Diseases, 2010, 69, 1913-1919.	0.9	159
35	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. Trials, 2013, 14, 324.	1.6	138
36	Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group. Journal of Rheumatology, 2006, 33, 9-15.	2.0	136

#	Article	IF	Citations
37	Minimal disease activity for rheumatoid arthritis: a preliminary definition. Journal of Rheumatology, 2005, 32, 2016-24.	2.0	132
38	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. Lancet Rheumatology, The, 2021, 3, e778-e788.	3.9	130
39	Outcomes from the Patient Perspective Workshop at OMERACT 6. Journal of Rheumatology, 2003, 30, 868-72.	2.0	129
40	Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis and Rheumatism, 2002, 46, 913-920.	6.7	125
41	Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Annals of the Rheumatic Diseases, 2006, 65, 637-641.	0.9	123
42	Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of the Rheumatic Diseases, 2005, 64, 1582-1587.	0.9	119
43	Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Annals of the Rheumatic Diseases, 2010, 69, 571-574.	0.9	117
44	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Annals of the Rheumatic Diseases, 2010, 69, 1015-1021.	0.9	117
45	World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. Journal of rheumatology Supplement, The, 1994, 41, 86-9.	2.2	117
46	Dutch–Flemish translation of 17 item banks from the Patient-Reported Outcomes Measurement Information System (PROMIS). Quality of Life Research, 2014, 23, 1733-41.	3.1	102
47	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 807-812.	0.9	99
48	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. Journal of Rheumatology, 2019, 46, 1021-1027.	2.0	97
49	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
50	Making an impact on mortality in rheumatoid arthritis: Targeting cardiovascular comorbidity. Arthritis and Rheumatism, 2004, 50, 1734-1739.	6.7	95
51	A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26…weeks. Annals of the Rheumatic Diseases, 2014, 73, 1071-1078.	0.9	91
52	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clinical and Experimental Research, 2016, 28, 47-58.	2.9	91
53	OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. Journal of Rheumatology, 1993, 20, 528-30.	2.0	90
54	Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. Journal of Rheumatology, 1993, 20, 555-6.	2.0	84

#	Article	IF	Citations
55	Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. Journal of the American Geriatrics Society, 2020, 68, 2955-2963.	2.6	83
56	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. Journal of Rheumatology, 2019, 46, 981-989.	2.0	82
57	A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain. Journal of Clinical Epidemiology, 2018, 95, 73-93.	5.0	81
58	Combination therapy in rheumatoid arthritis: updated systematic review. Rheumatology, 1998, 37, 612-619.	1.9	80
59	How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0. Journal of Rheumatology, 2014, 41, 1025-1030.	2.0	78
60	Defining remission in rheumatoid arthritis: Results of an initial american college of rheumatology/european league against rheumatism consensus conference. Arthritis and Rheumatism, 2009, 61, 704-710.	6.7	73
61	Evidence for predictive validity of remission on long‑term outcome in rheumatoid arthritis: A systematic review. Arthritis Care and Research, 2010, 62, 108-117.	3.4	73
62	Serum 14-3-3η is a Novel Marker that Complements Current Serological Measurements to Enhance Detection of Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 2104-2113.	2.0	72
63	The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. Annals of the Rheumatic Diseases, 2015, 74, 1004-1010.	0.9	71
64	Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis and Rheumatism, 2001, 44, 2242-2246.	6.7	70
65	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. Annals of the Rheumatic Diseases, 2016, 75, 1763-1769.	0.9	70
66	Comparison of long‑term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis and Rheumatism, 2012, 64, 3850-3855.	6.7	68
67	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1014-1020.	2.0	65
68	Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology, 2018, 57, 555-562.	1.9	63
69	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. Journal of Rheumatology, 2015, 42, 2190-2197.	2.0	62
70	Core outcome sets for research and clinical practice. Brazilian Journal of Physical Therapy, 2017, 21, 77-84.	2.5	62
71	Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. Journal of Rheumatology, 2003, 30, 1102-7.	2.0	62
72	Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. Annals of the Rheumatic Diseases, 2015, 74, 1233-1240.	0.9	61

#	Article	IF	Citations
73	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Journal of Rheumatology, 2019, 46, 1028-1035.	2.0	61
74	NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet, The, 2001, 357, 1222-1223.	13.7	60
75	Cohort Profile: Cohort Hip and Cohort Knee (CHECK) study. International Journal of Epidemiology, 2016, 45, 36-44.	1.9	59
76	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Annals of the Rheumatic Diseases, 2018, 77, 484-487.	0.9	59
77	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. Annals of the Rheumatic Diseases, 2022, 81, 925-936.	0.9	59
78	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. Journal of Rheumatology, 2014, 41, 1011-1015.	2.0	54
79	Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Annals of the Rheumatic Diseases, 2015, 74, 675-681.	0.9	53
80	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. RMD Open, 2016, 2, e000237.	3.8	52
81	Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*. British Journal of Dermatology, 2021, 185, 139-146.	1.5	52
82	The HOME Core outcome set for clinical trials of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2022, 149, 1899-1911.	2.9	51
83	Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. Arthritis Research and Therapy, 2019, 21, 228.	3.5	48
84	Confounding by Indication Probably Distorts the Relationship between Steroid Use and Cardiovascular Disease in Rheumatoid Arthritis: Results from a Prospective Cohort Study. PLoS ONE, 2014, 9, e87965.	2.5	47
85	Can We Decide Which Outcomes Should Be Measured in Every Clinical Trial? A Scoping Review of the Existing Conceptual Frameworks and Processes to Develop Core Outcome Sets. Journal of Rheumatology, 2014, 41, 986-993.	2.0	46
86	A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set. Trials, 2014, 15, 511.	1.6	46
87	Patient-reported outcomes in core domain sets for rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 705-712.	8.0	45
88	Minimal clinically important difference module: summary, recommendations, and research agenda. Journal of Rheumatology, 2001, 28, 452-4.	2.0	44
89	Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review. Journal of Clinical Epidemiology, 2018, 102, 23-37.	5.0	43
90	A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Research and Therapy, 2016, 18, 76.	3.5	42

#	Article	IF	Citations
91	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). Patient, 2017, 10, 141-152.	2.7	41
92	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Science Translational Medicine, 2019, 11, .	12.4	41
93	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. Lancet Rheumatology, The, 2020, 2, e583-e585.	3.9	40
94	Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11. Journal of Rheumatology, 2014, 41, 978-985.	2.0	39
95	Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Research and Therapy, 2015, 17, 266.	3.5	39
96	"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. Arthritis Care and Research, 2017, 69, 1134-1141.	3.4	39
97	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. Annals of the Rheumatic Diseases, 2014, 73, 391-395.	0.9	38
98	Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. Journal of Rheumatology, 2001, 28, 904-10.	2.0	37
99	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 2015, 74, 963-969.	0.9	36
100	Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard?. Arthritis and Rheumatism, 2003, 48, 1481-1483.	6.7	35
101	Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of "Truth" Content, Face, and Construct Validity. Journal of Rheumatology, 2014, 41, 1000-1004.	2.0	34
102	Validation of two PROMIS item banks for measuring social participation in the Dutch general population. Quality of Life Research, 2019, 28, 211-220.	3.1	33
103	Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. Lancet Rheumatology, The, 2022, 4, e417-e429.	3.9	33
104	Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain. PLoS ONE, 2015, 10, e0134094.	2.5	32
105	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials, 2018, 19, 67.	1.6	32
106	Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies. JMIR Formative Research, 2020, 4, e20165.	1.4	32
107	Is it time to revisit the role of ultrasound in rheumatoid arthritis management?. Annals of the Rheumatic Diseases, 2017, 76, 7-8.	0.9	31
108	Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. Annals of the Rheumatic Diseases, 2019, 78, 586-589.	0.9	31

#	Article	IF	Citations
109	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). Annals of the Rheumatic Diseases, 2021, 80, 840-847.	0.9	31
110	An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. Expert Opinion on Drug Safety, 2019, 18, 581-590.	2.4	30
111	The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example. Journal of Rheumatology, 2019, 46, 1394-1400.	2.0	30
112	A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism, 2014, 44, 271-282.	3.4	29
113	The COBRA trial 20 years later. Clinical and Experimental Rheumatology, 2011, 29, S46-51.	0.8	29
114	Detection of Subclinical Synovitis with Macrophage Targeting and Positron Emission Tomography in Patients with Rheumatoid Arthritis without Clinical Arthritis. Journal of Rheumatology, 2014, 41, 2145-2152.	2.0	28
115	Validity and measurement precision of the PROMIS physical function item bank and a content validity–driven 20-item short form in rheumatoid arthritis compared with traditional measures. Rheumatology, 2015, 54, kev265.	1.9	28
116	14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 1587-1594.	2.0	28
117	The Dutch–Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. Journal of Clinical Epidemiology, 2017, 87, 47-58.	5.0	28
118	Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. Rheumatology, 2017, 56, 1472-1478.	1.9	28
119	Graphics and statistics for cardiology: designing effective tables for presentation and publication. Heart, 2018, 104, 192-200.	2.9	28
120	Outcome measures for adherence data from a medication event monitoring system: A literature review. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 1-5.	1.5	27
121	Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. Annals of the Rheumatic Diseases, 2012, 71, 33-37.	0.9	26
122	A New Concept of Health Can Improve the Definition of Frailty. Calcified Tissue International, 2015, 97, 429-431.	3.1	26
123	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. Annals of the Rheumatic Diseases, 2016, 75, 1268-1271.	0.9	26
124	An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. Ocular Immunology and Inflammation, 2021, 29, 1154-1163.	1.8	26
125	Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high–dose prednisolone. Rheumatology, 2001, 40, 1231-1237.	1.9	25
126	Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: Argument in opposition. Arthritis and Rheumatism, 2005, 52, 1642-1645.	6.7	25

#	ARTICLE	IF	CITATIONS
127	A first step to assess harm and benefit in clinical trials in one scale. Journal of Clinical Epidemiology, 2010, 63, 627-632.	5.0	25
128	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. Journal of Rheumatology, 2016, 43, 182-186.	2.0	25
129	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. Journal of Rheumatology, 2019, 46, 976-980.	2.0	25
130	Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. Journal of Rheumatology, 2020, 47, 316-324.	2.0	25
131	The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Seminars in Arthritis and Rheumatism, 2021, 51, 1320-1330.	3.4	25
132	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Annals of the Rheumatic Diseases, 2022, 81, 1313-1322.	0.9	25
133	Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review. BMC Musculoskeletal Disorders, 2014, 15, 28.	1.9	24
134	Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open, 2021, 7, e001591.	3.8	24
135	Patient's global assessment of disease activity: What are we measuring?. Arthritis and Rheumatism, 2012, 64, 2811-2813.	6.7	23
136	Smartphone‐Assisted Patient‐Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial. Arthritis and Rheumatology, 2022, 74, 1737-1745.	5.6	23
137	IMPACT OF QUALITY ITEMS ON STUDY OUTCOME Treatments in Acute Lateral Ankle Sprains. International Journal of Technology Assessment in Health Care, 2000, 16, 1136-1146.	0.5	22
138	Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 406-409.	0.9	22
139	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody‐associated Vasculitis Using the OMERACT Process. Journal of Rheumatology, 2015, 42, 2204-2209.	2.0	22
140	Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. Seminars in Arthritis and Rheumatism, 2019, 48, 983-989.	3.4	21
141	OMERACT: an international initiative to improve outcome measurement in rheumatology. Clinical and Experimental Rheumatology, 2005, 23, S10-3.	0.8	21
142	Value of autopsy in internal medicine: a 1 -year prospective study of hospital deaths. European Journal of Clinical Investigation, 1988, 18, 314-320.	3.4	20
143	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. Journal of Rheumatology, 2014, 41, 994-999.	2.0	20
144	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. Journal of Rheumatology, 2016, 43, 203-207.	2.0	20

#	Article	IF	Citations
145	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. Radiotherapy and Oncology, 2016, 118, 251-256.	0.6	20
146	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. Rheumatology, 2017, 56, 1586-1596.	1.9	20
147	A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology, 2013, 52, 1435-1437.	1.9	19
148	Updating the OMERACT Filter at OMERACT 11. Journal of Rheumatology, 2014, 41, 975-977.	2.0	19
149	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2017, 46, 699-708.	3.4	19
150	A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15105.	1.0	19
151	Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: The paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Arthritis and Rheumatism, 2001, 44, 2703-2704.	6.7	18
152	Updating the OMERACT Filter: Discrimination and Feasibility. Journal of Rheumatology, 2014, 41, 1005-1010.	2.0	18
153	Calibration of the Dutchâ€Flemish <scp>PROMIS</scp> Pain Behavior item bank in patients with chronic pain. European Journal of Pain, 2016, 20, 284-296.	2.8	18
154	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. Seminars in Arthritis and Rheumatism, 2021, 51, 1125-1133.	3.4	18
155	Barriers and potential solutions in the recruitment and retention of older patients in clinical trialsâ€"lessons learned from six large multicentre randomized controlled trials. Age and Ageing, 2021, 50, 1988-1996.	1.6	17
156	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. Journal of Rheumatology, 2015, 42, 1971-1975.	2.0	15
157	Validating Rheumatoid Arthritis Remission Using the Patientsâ€™ Perspective: Results from a Special Interest Group at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1889-1893.	2.0	15
158	Zoledronate in the prevention of Pagetâ€™s (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to preventSQSTM1-mediated Pagetâ€™s disease of bone. BMJ Open, 2019, 9, e030689.	1.9	15
159	A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals: Figure 1. Annals of the Rheumatic Diseases, 2010, 69, 4-6.	0.9	14
160	Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. Journal of Clinical Epidemiology, 2010, 63, 813-814.	5.0	14
161	Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers. Journal of Rheumatology, 2014, 41, 1016-1024.	2.0	14
162	The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. Rheumatology, 2016, 55, 1615-1622.	1.9	14

#	Article	IF	Citations
163	Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials. ACR Open Rheumatology, 2019, 1, 251-257.	2.1	14
164	First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2020, 72, 1550-1559.	3.4	14
165	Patient global assessment to define remission in rheumatoid arthritis:quo vadis?. Annals of the Rheumatic Diseases, 2021, 80, 277-279.	0.9	14
166	One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. RMD Open, 2016, 2, e000313.	3.8	13
167	Observational studies on glucocorticoids are harmful!. Lupus Science and Medicine, 2017, 4, e000219.	2.7	13
168	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis—an international survey within the GLORIA study. Rheumatology, 2021, 60, 3334-3342.	1.9	13
169	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1116-1123.	0.9	13
170	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Current Medical Research and Opinion, 2011, 27, 315-325.	1.9	12
171	Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients. Transplantation Proceedings, 1988, 20, 371-5.	0.6	12
172	The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents. Annals of the Rheumatic Diseases, 2010, 69, 186-192.	0.9	11
173	Standing on the promises: First wave validation reports of the Patient-Reported Outcome Measurement Information System. Journal of Clinical Epidemiology, 2010, 63, 1167-1168.	5.0	11
174	RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials?. Annals of the Rheumatic Diseases, 2011, 70, 884-885.	0.9	11
175	Remission — keeping the patient experience front and centre. Nature Reviews Rheumatology, 2017, 13, 573-574.	8.0	11
176	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. Journal of Rheumatology, 2017, 44, 1916-1919.	2.0	11
177	Cross‐Cultural and Construct Validity of the Animated Activity Questionnaire. Arthritis Care and Research, 2017, 69, 1349-1359.	3.4	11
178	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. Journal of Rheumatology, 2019, 46, 1159-1163.	2.0	11
179	Dutch reference values for the Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health (PROMIS-GH). Journal of Patient-Reported Outcomes, 2021, 5, 38.	1.9	11
180	Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Rheumatology, 2022, 61, 1867-1876.	1.9	11

#	Article	IF	Citations
181	Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open, 2022, 8, e002035.	3.8	11
182	Trilateral retinoblastoma. , 2000, 88, 965-966.		10
183	What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?. Arthritis Care and Research, 2015, 67, 1202-1209.	3.4	10
184	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. Journal of Rheumatology, 2020, 47, 1379-1384.	2.0	10
185	Cyclosporine nephrotoxicity in rheumatoid arthritis: no effect of short term misoprostol treatment. Journal of Rheumatology, 1992, 19, 534-7.	2.0	10
186	Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. Journal of Rheumatology, 2007, 34, 661-3.	2.0	10
187	Relapse–remission and remission–relapse switches in rheumatoid arthritis patients were modeled by random effects. Journal of Clinical Epidemiology, 2009, 62, 1085-1094.	5.0	9
188	A new graph and scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. Journal of Clinical Epidemiology, 2010, 63, 633-637.	5.0	9
189	Syk kinase inhibitors for rheumatoid arthritis: Trials and tribulations. Arthritis and Rheumatism, 2011, 63, 329-330.	6.7	9
190	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. Arthritis Research and Therapy, 2020, 22, 177.	3.5	9
191	Clinical measures in rheumatoid arthritis: which are most useful in assessing patients?. Journal of Rheumatology, 1994, 21, 1773-4.	2.0	9
192	The validity of radiography as outcome measure in rheumatoid arthritis. Journal of Rheumatology, 1995, 22, 1783-6.	2.0	9
193	Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?. Best Practice and Research in Clinical Rheumatology, 2004, 18, 21-29.	3.3	8
194	Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis. Arthritis Research and Therapy, 2016, 18, 22.	3.5	8
195	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. Arthritis Care and Research, 2017, 69, 989-996.	3.4	8
196	Designing effective graphs to get your message across. Annals of the Rheumatic Diseases, 2018, 77, 833-839.	0.9	8
197	PROMIS Physical Function Short Forms Display Item- and Scale-Level Characteristics at Least as Good as the Roland Morris Disability Questionnaire in Patients With Chronic Low Back Pain. Archives of Physical Medicine and Rehabilitation, 2020, 101, 297-308.	0.9	8
198	Higher body mass index is associated with lower foot health in patients with rheumatoid arthritis: baseline results of the Amsterdam-Foot cohort. Scandinavian Journal of Rheumatology, 2020, 49, 186-194.	1.1	8

#	Article	IF	Citations
199	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count. Rheumatology, 2021, 60, 5239-5246.	1.9	8
200	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Seminars in Arthritis and Rheumatism, 2021, 51, 1108-1112.	3.4	8
201	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. Seminars in Arthritis and Rheumatism, 2021, 51, 1139-1145.	3.4	8
202	Prevention or Retardation of Joint Damage in Rheumatoid Arthritis. Drugs, 2002, 62, 1717-1724.	10.9	7
203	Null bar and null zone are better than the error bar to compare group means in graphs. Journal of Clinical Epidemiology, 2004, 57, 712-715.	5.0	7
204	How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.. Journal of Rheumatology, 2009, 36, 2114-2121.	2.0	7
205	Nonâ€overlapping American College of Rheumatology response rates: A better way to report response in rheumatoid arthritis Clinical Trials. Arthritis and Rheumatism, 2010, 62, 3524-3527.	6.7	7
206	Biological treatment in rheumatoid arthritis: when to stop?. Lancet, The, 2014, 383, 288-289.	13.7	7
207	Recommended core outcome instruments for healthâ€related quality of life, longâ€term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. British Journal of Dermatology, 2020, 185, 139.	1.5	7
208	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. Seminars in Arthritis and Rheumatism, 2021, 51, 601-606.	3.4	7
209	Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort. Arthritis Research and Therapy, 2021, 23, 217.	3.5	7
210	Diagnosis for early stage knee osteoarthritis: probability stratification, internal and external validation; data from the CHECK and OAI cohorts. Seminars in Arthritis and Rheumatism, 2022, 55, 152007.	3.4	7
211	Outcome measures in rheumatoid arthritis: the OMERACT process. Expert Review of Clinical Immunology, 2007, 3, 271-275.	3.0	6
212	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. Journal of Rheumatology, 2016, 43, 1024-1026.	2.0	6
213	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. Journal of Rheumatology, 2019, 46, 1173-1178.	2.0	6
214	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. Journal of Rheumatology, 2019, 46, 1406-1408.	2.0	6
215	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. Annals of the Rheumatic Diseases, 2021, 80, 242-249.	0.9	6
216	Letâ€™s stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!. Annals of the Rheumatic Diseases, 2016, 75, e68-e68.	0.9	5

#	Article	IF	Citations
217	Assessment of Health Outcomes. , 2017, , 496-508.		5
218	Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism, 2020, 50, 1400-1405.	3.4	5
219	High Prevalence of Previously Undiagnosed Axial Spondyloarthritis in Patients Referred With Anterior Uveitis and Chronic Back Pain: The SpEYE Study. Journal of Rheumatology, 2022, 49, 680-687.	2.0	5
220	Three Months of Glucocorticoids in Rheumatoid Arthritis: A Bridge Too Short?. Arthritis and Rheumatology, 2022, 74, 1609-1611.	5.6	5
221	Progress Towards Optimal Trial End-Points in Rheumatoid Arthritis. BioDrugs, 1997, 7, 40-50.	4.6	4
222	A call for pragmatic treatment trials in rheumatoid arthritis. Nature Clinical Practice Rheumatology, 2008, 4, 292-293.	3.2	4
223	â€œSpydergramsâ€•to depict the results of the Short Form-36 questionnaire: a work in progress. Journal of Clinical Epidemiology, 2013, 66, 243-246.	5.0	4
224	Patient-reported Remission in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 350-352.	2.0	4
225	OP0151â€¦Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis:. Annals of the Rheumatic Diseases, 2013, 71, 104.3-105.	0.9	4
226	THU0154â€¦Adverse effects of glucocorticoid therapy in rheumatoid arthritis (RA): A systematic review and meta-analysis of randomized controlled trials:. Annals of the Rheumatic Diseases, 2013, 71, 207.3-208.	0.9	4
227	Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology. Arthritis Care and Research, 2016, 68, 1206-1210.	3.4	4
228	The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort. Journal of Clinical Medicine, 2020, 9, 3374.	2.4	4
229	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. Osteoporosis International, 2021, 32, 1441-1449.	3.1	4
230	Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis. Calcified Tissue International, 1998, 63, 93-97.	3.1	4
231	Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies. Disease Management and Health Outcomes, 2000, 8, 87-97.	0.4	3
232	Response to: â€˜Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!â€™ by Baker <i>et al</i>. Annals of the Rheumatic Diseases, 2017, 76, e13-e13.	0.9	3
233	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3Ã—3 Methodology Applied to Two Active Comparator Trials. Arthritis Care and Research, 2019, 71, 319-322.	3.4	3
234	Long-term Glucocorticoid Use in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1342-1342.	2.0	3

#	Article	IF	Citations
235	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. Annals of the Rheumatic Diseases, 2020, 79, 1269-1276.	0.9	3
236	P187â€ƒSecukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naive patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. Rheumatology, 2021, 60, .	1.9	3
237	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Seminars in Arthritis and Rheumatism, 2021, 51, 607-617.	3.4	3
238	Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Seminars in Arthritis and Rheumatism, 2021, 51, 1360-1369.	3.4	3
239	Assessment of Health Outcomes. , 2013, , 462-475.e3.		3
240	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. RMD Open, 2017, 3, e000502.	3.8	3
241	Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET. RMD Open, 2022, 8, e002108.	3.8	3
242	Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. Clinical and Experimental Rheumatology, 2018, 36, 362-370.	0.8	3
243	The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study. Clinical Rheumatology, 2022, 41, 2525-2531.	2.2	3
244	Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years. Annals of the Rheumatic Diseases, 2022, 81, 1196-1197.	0.9	3
245	Methodology of combination trials. Seminars in Immunopathology, 2001, 23, 27-33.	4.0	2
246	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. Drug Information Journal, 2006, 40, 111-116.	0.5	2
247	Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. Rheumatology, 2011, 50, 1732-1736.	1.9	2
248	The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2012, 71, A5.1-A5.	0.9	2
249	THU0244â€…14-3-3Eta is an Independent Predictor of Radiographic Changes in Early RA and Higher Titres Inform A Higher Likelihood of Joint Damage Progression. Annals of the Rheumatic Diseases, 2014, 73, 266.2-266.	0.9	2
250	OP0276â€…Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomised Trials. Annals of the Rheumatic Diseases, 2015, 74, 176.2-177.	0.9	2
251	Excessive Pricing Causes Poor Access to Biologics. Journal of Rheumatology, 2018, 45, 876.1-876.	2.0	2
252	OP0226â€…SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2

#	Article	IF	Citations
253	FRI0118â€¦INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
254	Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Metaâ€Regression Analyses. Arthritis Care and Research, 2020, 72, 1490-1496.	3.4	2
255	Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. Annals of the Rheumatic Diseases, 2020, 79, 301-302.	0.9	2
256	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. RMD Open, 2021, 7, e001560.	3.8	2
257	The GLORIA adherence subproject: problems and randomization mistakes. Journal of Trial and Error, 2022, 2, 54-59.	0.5	2
258	Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Rheumatology Advances in Practice, 2022, 6, rkab089.	0.7	2
259	Bias in its coat of many colors. Journal of Rheumatology, 2001, 28, 1747-8.	2.0	2
260	Progress toward the development of a new definition of remission in rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2010, 68, 140-2.	0.7	2
261	SAT0037â€¦Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk. Annals of the Rheumatic Diseases, 2014, 73, 602.1-602.	0.9	1
262	The controversy of using PGA to define remission in RA. Nature Reviews Rheumatology, 2018, 14, 245-245.	8.0	1
263	Effects of Co-medication with Glucocorticoids in Biologics Trials. Journal of Rheumatology, 2018, 45, 1605.1-1605.	2.0	1
264	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. Seminars in Arthritis and Rheumatism, 2019, 49, 218-221.	3.4	1
265	Response to: â€˜Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS studyâ€™ by Marotte <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e82-e82.	0.9	1
266	OP0226â€¦TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY. Annals of the Rheumatic Diseases, 2021, 80, 136-137.	0.9	1
267	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. Trials, 2021, 22, 406.	1.6	1
268	SAT0189â€¦Dynamics of circulating tnf during adalimumab treatment of rheumatoid arthritis using a novel drug-tolerant tnf assay. , 2018, , .		1
269	SAT0551â€¦WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2020, 79, 1233.2-1233.	0.9	1
270	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology. , 0, , 41-62.		1

#	Article	IF	Citations
271	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology. , 0, , 19-24.		1
272	Lessons Learned from Disaster Research: The Medical Evaluation of the Disaster in Volendam, The Netherlands. Prehospital and Disaster Medicine, 2005, 20, 68-68.	1.3	0
273	SAT0531â€¦Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis. Annals of the Rheumatic Diseases, 2013, 72, A761.2-A761.	0.9	0
274	AB1360â€¦Gastrointestinal events in patients receiving NSAIDs for rheumatic diseases in routine practice: The pan-european evidence study. Annals of the Rheumatic Diseases, 2013, 71, 715.13-715.	0.9	0
275	AB0306â€¦The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept. Annals of the Rheumatic Diseases, 2013, 71, 655.2-655.	0.9	0
276	FRI0521â€¦A framework and process to develop core outcome measurement sets for clinical trials in rheumatology: omeract filter 2.0. Annals of the Rheumatic Diseases, 2013, 72, A550.3-A551.	0.9	0
277	SAT0130â€¦Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials. Annals of the Rheumatic Diseases, 2013, 72, A625.1-A625.	0.9	0
278	AB0184â€¦Applying the conrew score to camera -trial ii data. Annals of the Rheumatic Diseases, 2013, 72, A842.1-A842.	0.9	0
279	THU0045â€¦Score and framingham predict cv disease incidence in RA patients better than intima-media thickness:. Annals of the Rheumatic Diseases, 2013, 71, 168.2-168.	0.9	0
280	SAT0037â€¦14-3-3 ETA Sero-Positivity Marks More Severe Disease and Titres Inform Response to Therapy, also in Patients with Lower Crp. Annals of the Rheumatic Diseases, 2013, 72, A592.2-A592.	0.9	0
281	AB0779â€¦7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP &) Tj ETQq1 1 0.784314 rgBT /	0.9	0
282	THU0563â€¦Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.2-377.	0.9	0
283	THU0564â€¦Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain. Annals of the Rheumatic Diseases, 2014, 73, 377.3-378.	0.9	0
284	SAT0051â€¦Alternative Ways to Analyze Remission: Applying the Conrew Score and Patient Vector Graph to Camera â€"Trial II Data. Annals of the Rheumatic Diseases, 2014, 73, 607.3-608.	0.9	0
285	FRI0224â€¦A New Method to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: the Animated Activity Questionnaire (AAQ): Part 1. Development, Validity and Reliability. Annals of the Rheumatic Diseases, 2014, 73, 463.3-464.	0.9	0
286	AB0466â€¦Glucocorticoid Effect on Radiographic Progression in Rheumatoid Arthritis BIOLOGICS Trials. Annals of the Rheumatic Diseases, 2014, 73, 961.4-962.	0.9	0
287	OP0202â€¦Omeract Method of Combined Reporting of Benefit and Harm Applied to the TEAR Trial:. Annals of the Rheumatic Diseases, 2014, 73, 139.1-139.	0.9	0
288	THU0599â€¦Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 418.1-418.	0.9	0

#	ARTICLE	IF	CITATIONS
289	OP0013â€¦Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2015, 74, 69.1-69.	0.9	0
290	Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. Arthritis Care and Research, 2015, 67, 1471-1474.	3.4	0
291	OP0314â€¦Is Cardiovascular Risk Management in Patients with Rheumatoid Arthritis Effective? Two Year Follow Up Reveals Unexpected Rise in Cardiovascular Risk!. Annals of the Rheumatic Diseases, 2015, 74, 192.1-192.	0.9	0
292	SAT0620â€¦Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 894.2-894.	0.9	0
293	OP0262â€¦Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial. Annals of the Rheumatic Diseases, 2016, 75, 157.2-157.	0.9	0
294	THU0104â€¦Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 217.1-217.	0.9	0
295	FRI0229â€¦Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. Annals of the Rheumatic Diseases, 2016, 75, 516.1-516.	0.9	0
296	THU0064â€¦Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 201.1-201.	0.9	0
297	OP0106â€¦Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 95.1-95.	0.9	0
298	THU0635â€¦Defining The Optimal Biological Monotherapy in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis of Randomised Trials. Annals of the Rheumatic Diseases, 2016, 75, 423.3-424.	0.9	0
299	THU0062â€¦Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline. Annals of the Rheumatic Diseases, 2016, 75, 200.2-200.	0.9	0
300	SAT0127â€¦Unfavorable body composition already at the onset of clinical arthritis. , 2017, , .		0
301	THU0712â€¦Dutch norm scores for four dutch-flemish promis item banks important for patients with rheumatoid arthritis. , 2017, , .		0
302	THU0677â€¦Outcome measurement instruments for safety in rheumatology: a scoping review of available instruments to inform the omeract safety working group. , 2017, , .		0
303	Response to: Comment on lâ€™Ami <i>et al</i> titled â€˜Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trialâ€™ by den Broeder <i>et al</i>. Annals of the Rheumatic Diseases, 2018, 77, e68-e68.	0.9	0
304	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. ReumatologÃa ClÃnica, 2019, 15, 311-314.	0.5	0
305	217â€ƒResults of a patient survey on feasibility and face validity of outcome measures for intended use in future studies enrolling participants with polymyalgia rheumatica. Rheumatology, 2019, 58, .	1.9	0
306	Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. Annals of Internal Medicine, 2019, 171, 679.	3.9	0

#	Article	IF	Citations
307	OP0014â€¦NO ASSOCIATION BETWEEN THE PROPORTION OF ELDERLY PEOPLE AND TRIAL RETENTION IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS TRIALS: A SYSTEMATIC REVIEW WITH META-REGRESSION ANALYSES. , 2019, , .		0
308	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. ReumatologÃa ClÃnica (English Edition), 2019, 15, 311-314.	0.3	0
309	Reply. Arthritis Care and Research, 2019, 71, 577-578.	3.4	0
310	Mortality has improved in RA, but we must remain vigilant. Response to: â€˜Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RAâ€™ by Matthijssen <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e125-e125.	0.9	0
311	Public/private partnerships, at what price?. Annals of the Rheumatic Diseases, 2022, 81, e211-e211.	0.9	0
312	AB0160â€¦HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 1107.1-1107.	0.9	0
313	POS0197â€¦RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 314.1-314.	0.9	0
314	AB1335-HPRâ€¦HEALTH PROFESSIONALSâ€™ PERSPECTIVE ON THE BENEFITS AND RISKS OF LOW-DOSE GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS â€“ AN INTERNATIONAL SURVEY OF 444 HEALTH PROFESSIONALS. Annals of the Rheumatic Diseases, 2020, 79, 1955.1-1956.	0.9	0
315	AB1223â€¦RHEUMATOID ARTHRITIS PATIENTS INCLUDED IN GLUCOCORTICOID TRIALS MOSTLY RESEMBLE THOSE SEEN IN OBSERVATIONAL COHORTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Annals of the Rheumatic Diseases, 2020, 79, 1903.1-1903.	0.9	0
316	PARE0004â€¦PATIENT PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS â€“ AN INTERNATIONAL SURVEY OF 1344 PATIENTS. Annals of the Rheumatic Diseases, 2020, 79, 1288.2-1288.	0.9	0
317	THU0614-HPRâ€¦ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS. Annals of the Rheumatic Diseases, 2020, 79, 548.2-550.	0.9	0
318	Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies. Annals of the Rheumatic Diseases, 2022, , annrheumdis-2021-221775.	0.9	0
319	More erroneous statements about the use of frequentist statistical methods in medical research. Clinical and Experimental Rheumatology, 2019, 37 Suppl 122, 4.	0.8	0
320	Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross sectional study. Reply. Rheumatology Advances in Practice, 2022, 6, rkac011.	0.7	0
321	Whole body macrophage PET imaging for disease activity assessment in early rheumatoid arthritis. Journal of Rheumatology, 2022, , jrheum.210928.	2.0	0
322	P253â€‰Ultrasound demonstrates continued improvement in psoriatic arthritis synovitis and enthesitis with secukinumab: 52-week results from a Phase 3 study. Rheumatology, 2022, 61, .	1.9	0